Distinguished in Becker Muscular Dystrophy

Dr. John F. Brandsema

Pediatric Neurology | Neurology
University Of Penn-Medical Group
3400 Civic Ctr Blvd 1, Abram Cancer Ctr Pacam 1 Flr, 
Philadelphia, PA 
Distinguished in Becker Muscular Dystrophy
University Of Penn-Medical Group
3400 Civic Ctr Blvd 1, Abram Cancer Ctr Pacam 1 Flr, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Brandsema is a Pediatric Neurologist and a Neurologist in Philadelphia, Pennsylvania. Dr. Brandsema and is rated as a Distinguished provider by MediFind in the treatment of Becker Muscular Dystrophy. His top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, and Thymectomy.

His clinical research consists of co-authoring 28 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles and participated in 8 clinical trials in the study of Becker Muscular Dystrophy.

Specialties
Pediatric Neurology
Neurology
Licenses
Neurology with Special Qualifications in Neurology in PA
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UNIVERSITY OF PENN-MEDICAL GROUP
3400 Civic Ctr Blvd 1, Abram Cancer Ctr Pacam 1 Flr, Philadelphia, PA 19104
Other Locations
UNIVERSITY OF PENN-MEDICAL GROUP
3400 Spruce St, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Genetic
Study Phase: Phase 3
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Expanded Access Protocol (EAP) of Idebenone in Patients With Duchenne Muscular Dystrophy
Expanded Access Protocol (EAP) of Idebenone in Patients With Duchenne Muscular Dystrophy
Enrollment Status: No_longer_available
Publish Date: April 21, 2023
Intervention Type: Drug
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Enrollment Status: Terminated
Publish Date: January 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

28 Total Publications

Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States: A Cohort Study Using Health Care Claims Databases.
Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States: A Cohort Study Using Health Care Claims Databases.
Journal: Neurology
Published: June 09, 2025
Similar Doctors
Distinguished in Becker Muscular Dystrophy
Dr. Gihan I. Tennekoon
Neurology
Distinguished in Becker Muscular Dystrophy
Dr. Gihan I. Tennekoon
Neurology
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Neurology, 
Philadelphia, PA 
 (0.1 mi)
215-590-1719
Languages Spoken:
English
See accepted insurances

Gihan Tennekoon is a Neurologist in Philadelphia, Pennsylvania. Dr. Tennekoon and is rated as a Distinguished provider by MediFind in the treatment of Becker Muscular Dystrophy. Their top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Primary Lateral Sclerosis.

Advanced in Becker Muscular Dystrophy
Dr. Mena T. Scavina
Pediatric Neurology | Neurology
Advanced in Becker Muscular Dystrophy
Dr. Mena T. Scavina
Pediatric Neurology | Neurology
A.i. Dupont Hospital For Children, 1600 Rockland Road, 
Wilmington, DE 
 (21.2 mi)
302-651-4000
Languages Spoken:
English
See accepted insurances

Mena Scavina is a Pediatric Neurologist and a Neurologist in Wilmington, Delaware. Dr. Scavina and is rated as an Advanced provider by MediFind in the treatment of Becker Muscular Dystrophy. Their top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Primary Lateral Sclerosis, and Spinal Muscular Atrophy (SMA).

Advanced in Becker Muscular Dystrophy
Dr. Terry D. Heiman-Patterson
Neurology
Advanced in Becker Muscular Dystrophy
Dr. Terry D. Heiman-Patterson
Neurology

Temple Faculty Practice Plan Inc

3509 N Broad St, 
Philadelphia, PA 
 (4.6 mi)
215-707-2111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Terry Heiman-Patterson is a Neurologist in Philadelphia, Pennsylvania. Dr. Heiman-Patterson and is rated as an Elite provider by MediFind in the treatment of Becker Muscular Dystrophy. Her top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy Type 3, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brandsema's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile